Prospects for Venetoclax in Myelodysplastic Syndromes

被引：12

作者：

Garcia, Jacqueline S. ^{[1
]}

机构：

[1] Harvard Med Sch, Dana Farber Canc Inst, 450 Brookline Ave,Dana 2054, Boston, MA 02215 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2020年 / 34卷 / 02期

关键词：

Venetoclax; MDS; Apoptosis; BCL-2; BCL-X-L; ACUTE MYELOID-LEUKEMIA; CLONAL EVOLUTION; FAMILY PROTEINS; APOPTOSIS; DEATH; INHIBITION; MODULATION; SECONDARY; TARGETS;

D O I：

10.1016/j.hoc.2019.10.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BCL-2 is an antiapoptotic protein that plays a critical role acute and chronic leukemias. Venetoclax is an orally selective BCL-2 inhibitor and BH3 mimetic approved in chronic lymphocytic leukemia and in combination with low dose cytarabine or hypomethylating agent in acute myeloid leukemia for the treatment of patients unfit for intensive chemotherapy. This article reviews the biology of BCL-2, focusing on its relationship to the myeloid microenvironment, and discusses the rationale for BCL-2 inhibition in myelodysplastic syndrome (MDS). Clinical trials testing venetoclax in MDS patients are under way. Potential biomarkers for clinical response to BCL-2 inhibition are discussed. Therapeutic opportunities for venetoclax in the therapeutic landscape of MDS are explored.

引用

页码：441 / +

页数：9

共 37 条

[1] The Bcl-2 apoptotic switch in cancer development and therapy [J].

Adams, J. M. ;

Cory, S. .

ONCOGENE, 2007, 26 (09) :1324-1337

[2] Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia [J].

Aldoss, Ibrahim ;

Yang, Dongyun ;

Aribi, Ahmed ;

Ali, Haris ;

Sandhu, Karamjeet ;

Al Malki, Monzr M. ;

Mei, Matthew ;

Salhotra, Amandeep ;

Khaled, Samer ;

Nakamura, Ryotaro ;

Snyder, David ;

O'Donnell, Margaret ;

Stein, Anthony S. ;

Forman, Stephen J. ;

Marcucci, Guido ;

Pullarkat, Vinod .

HAEMATOLOGICA, 2018, 103 (09) :E404-E407

[3] BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies [J].

Bogenberger, J. M. ;

Kornblau, S. M. ;

Pierceall, W. E. ;

Lena, R. ;

Chow, D. ;

Shi, C-X ;

Mantei, J. ;

Ahmann, G. ;

Gonzales, I. M. ;

Choudhary, A. ;

Valdez, R. ;

Camoriano, J. ;

Fauble, V. ;

Tiedemann, R. E. ;

Qiu, Y. H. ;

Coombes, K. R. ;

Cardone, M. ;

Braggio, E. ;

Yin, H. ;

Azorsa, D. O. ;

Mesa, R. A. ;

Stewart, A. K. ;

Tibes, R. .

LEUKEMIA, 2014, 28 (08) :1657-1665

[4] Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members [J].

Certo, Michael ;

Moore, Victoria Del Gaizo ;

Nishino, Mari ;

Wei, Guo ;

Korsmeyer, Stanley ;

Armstrong, Scott A. ;

Letai, Anthony .

CANCER CELL, 2006, 9 (05) :351-365

[5] BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis [J].

Cheng, EHYA ;

Wei, MC ;

Weiler, S ;

Flavell, RA ;

Mak, TW ;

Lindsten, T ;

Korsmeyer, SJ .

MOLECULAR CELL, 2001, 8 (03) :705-711

[6] RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML [J].

Crews, Leslie A. ;

Balaian, Larisa ;

Delos Santos, Nathaniel P. ;

Leu, Heather S. ;

Court, Angela C. ;

Lazzari, Elisa ;

Sadarangani, Anil ;

Zipeto, Maria A. ;

La Clair, James J. ;

Villa, Reymundo ;

Kulidjian, Anna ;

Storb, Rainer ;

Morris, Sheldon R. ;

Ball, Edward D. ;

Burkart, Michael D. ;

Jamieson, Catriona H. M. .

CELL STEM CELL, 2016, 19 (05) :599-612

[7] Clonal evolution in myelodysplastic syndromes [J].

da Silva-Coelho, Pedro ;

Kroeze, Leonie I. ;

Yoshida, Kenichi ;

Koorenhof-Scheele, Theresia N. ;

Knops, Ruth ;

van de Locht, Louis T. ;

de Graaf, Aniek O. ;

Massop, Marion ;

Sandmann, Sarah ;

Dugas, Martin ;

Stevens-Kroef, Marian J. ;

Cermak, Jaroslav ;

Shiraishi, Yuichi ;

Chiba, Kenichi ;

Tanaka, Hiroko ;

Miyano, Satoru ;

de Witte, Theo ;

Blijlevens, Nicole M. A. ;

Muus, Petra ;

Huls, Gerwin ;

van der Reijden, Bert A. ;

Ogawa, Seishi ;

Jansen, Joop H. .

NATURE COMMUNICATIONS, 2017, 8

[8] BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents [J].

Deng, Jing ;

Carlson, Nicole ;

Takeyama, Kunihiko ;

Dal Cin, Paola ;

Shipp, Margaret ;

Letai, Anthony .

CANCER CELL, 2007, 12 (02) :171-185

[9] Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML [J].

DiNardo, C. D. ;

Stein, E. M. ;

de Botton, S. ;

Roboz, G. J. ;

Altman, J. K. ;

Mims, A. S. ;

Swords, R. ;

Collins, R. H. ;

Mannis, G. N. ;

Pollyea, D. A. ;

Donnellan, W. ;

Fathi, A. T. ;

Pigneux, A. ;

Erba, H. P. ;

Prince, G. T. ;

Stein, A. S. ;

Uy, G. L. ;

Foran, J. M. ;

Traer, E. ;

Stuart, R. K. ;

Arellano, M. L. ;

Slack, J. L. ;

Sekeres, M. A. ;

Willekens, C. ;

Choe, S. ;

Wang, H. ;

Zhang, V. ;

Yen, K. E. ;

Kapsalis, S. M. ;

Yang, H. ;

Dai, D. ;

Fan, B. ;

Goldwasser, M. ;

Liu, H. ;

Agresta, S. ;

Wu, B. ;

Attar, E. C. ;

Tallman, M. S. ;

Stone, R. M. ;

Kantarjian, H. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25) :2386-2398

[10] Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia [J].

DiNardo, Courtney D. ;

Pratz, Keith ;

Pullarkat, Vinod ;

Jonas, Brian A. ;

Arellano, Martha ;

Becker, Pamela S. ;

Frankfurt, Olga ;

Konopleva, Marina ;

Wei, Andrew H. ;

Kantarjian, Hagop M. ;

Xu, Tu ;

Hong, Wan-Jen ;

Chyla, Brenda ;

Potluri, Jalaja ;

Pollyea, Daniel A. ;

Letai, Anthony .

BLOOD, 2019, 133 (01) :7-17

← 1 2 3 4 →